Description
The study shows C1q drives synaptosome phagocytosis leading to proteasome-dependent synaptic degradation, but the mechanistic connection between complement-mediated phagocytosis and proteasome activation is unclear. This pathway could represent a key therapeutic target for synaptic preservation in AD.
Gap type: unexplained_observation Source paper: Complement C1q-Targeted Microglial Membrane Camouflaged Nanolipid Carriers for Synaptic Protection in Alzheimer’s Disease: A Bioinspired Alectinib Delivery Strategy. (2026, Nano letters, PMID:41114949)
Resolution criteria
Gap closes when: (1) A mechanistic study using pharmacological inhibition or genetic knockout of candidate intermediate proteins (e.g. ubiquitin ligases, autophagy receptors) between the C1q-binding event and proteasome activation demonstrates >= 50% reduction in synaptic degradation with FDR < 0.05; and (2) proximity labeling (BioID or TurboID) of C1q-coated synaptosomes identifies at least one validated adaptor protein linking complement tagging to the ubiquitin-proteasome pathway; and (3) rescue of synaptic density by proteasome inhibitor is reproduced in at least 2 independent systems (in vitro and in vivo). Deliverable: mechanistic model with molecular evidence and quantitative synaptic density data.